December 28, 2023 7:58am

With just two sessions left in the trading year

Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

If you want facts to interpret share pricing realities to save your portfolio for cautious decisions, bookmark this site!

Never leave an investor uninformed!

Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

 

The pre-open Dow futures are DOWN -0.14% or (-52 points), the S&P is UP +0.03% or (+1 points) as the Nasdaq is UP +0.27% or (+47 points)

Stock futures are mixed and fluctuating on Thursday,

European stocks were negative as it moved,

Asia Pacific markets were mixed with Japan down.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday, indexes closed up …. as the Dow closed UP +111.19 points or +0.30%, the S&P closed UP +6.83 points or +0.14% while the Nasdaq closed UP +24.60 points or +0.16%

Economic Data Docket: data on jobless claims and pending home sales

 

Wednesday, RegMed Investors (RMi) Closing Bell: “a Santa Claus rally in a short week of pitstops. There were no catalysts and minimal trading activity to see the extension of an upside trend.” …  https://www.regmedinvestors.com/articles/13260

 

Q4:  December – 1 holiday, 8 positive and 10 negative closes

  • November – 11 positives, 1 holiday and 10 negative closes
  • October – 1 sick day, 9 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications; it’s just mixed signals, followed by a weak aftermarket as markets allowing for December’s end … take gains as to those who WILL seek to recapitalize cash positions by discounted stock and pricing offerings!

 

If I was to make a “bet”:

  • Blueprint Medicine (BPMC) closed up +$2.03 after Tuesday’s +$1.98 with a negative -$1.38 or -1.49% pre-open indication

 

The BOTTOM LINE: I got the “vid” – covid – didn’t make for a happy, happy holiday week pre–New Year but I make the most of is as I was cook, cleaner, bottle washer (plus drinker) and playing doctor for the “babe” wasn’t fun as

What has been said to date …

  • Again, and again – I say what changes … as I reiterate … “I remain a skeptic, as electronic trading remains the impetus to, I believe a cell and gene therapy sector’s artificial high” … as proven today yet again!
  • Thin liquidity conditions exacerbate the so-called 'Santa Claus rally' in equities ahead of the turn of the year. 

 

“The market looks increasingly overbought; the Nasdaq is extended from the 50-day line while sentiment indicators point to elevated bullishness. All of that continues to suggest another market pause or pullback is likely. Investors waiting to sell stocks until January for tax reasons may be delaying that potential pullback, but ultimately that could make the eventual pullback more significant.” <IBD>

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.